BUHLMANN News

Monoclonal antibody testing for fecal calprotectin is superior to Polyclonal Testing of Fecal Calprotectin and Lactoferrin to Identify Organic Intestinal Disease in Patients with Adominal Discomfort

BÜHLMANN fCAL® ELISA Citation Burri E, Manz M., Rothen C, Rossi L,Beglinger C, Lehmann S. Monoclonal antibody testing for fecal calprotectin is superior to polyclonal testing of fecal calprotectin and lactoferrin to identify organic intestinal disease in patients with abdominal discomfort. Clinica Chimica Acta. 2013 Feb; 416: 41-47.  doi: 10.1016/j.cca.2012.11.008 Highlights from this Publication “…we demonstrated, that the
Continue Reading

Comparison of Six Different Calprotectin Assays for the Assessment of Inflammatory Bowel Disease

Quantum Blue® fCAL Citation Labaere, D, Smismans A, Olmen A, Christiaens P, D’Haens G, Moons V, Cuyle P, Frans J, and Bossuyt P. Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease, United European Gastroenterology J. 2014 Feb; 2(1): 30–37.  doi:  10.1177/2050640613518201 Highlight from this Publication "The EliA [Phadia] cut off for diagnosis was optimal at a level of 15 mg/g. This
Continue Reading

Fecal Calprotectin: Towards a Standardized Use for Inflammatory Bowel Disease Management in Routine Practice

Value of Fecal Calprotectin in the Diagnosis of IBD: Edouard, Louis. Fecal calprotectin: towards a standardized use for inflammatory bowel disease management in routine practice. Journal of Crohn's and Colitis, 2015, 1–3 doi:10.1093/ecco-jcc/jju012. “…fecal calprotectin as a unique first line test would be sufficient to decide in which patient to perform further endoscopic or medical imaging
Continue Reading

Flow CAST® eBook- Kinase Inhibition Assay for BTK, SYK, and PI3K Activity

Flow CAST® eBook Testing Potency and Efficacy of Inhibitors of PI3K, PI3K, BTK and SYK Activity Biomarker assays are developed specifically for pharmacokinetic and pharmacodyamic (PK/PD) models during drug discovery and are often used to test efficacy and toxicity. Inhibitors of PI3K, SYK and BTK pathways are a large focus for pharmaceutical companies with several
Continue Reading

A New Rapid Quantitative Test for Fecal Calprotectin Predicts Endoscopic Activity in Ulcerative Colitis

Quantum Blue®  fCAL Citation Lobatón T, Rodríguez-Moranta F, Lopez A, Sánchez E, Rodríguez-Alonso L, Guardiola J. A new rapid quantitative test for fecal calprotectin predicts endoscopic activity in ulcerative colitis.   Inflamm Bowel Dis. 2013 Apr;19(5):1034-42. doi: 10.1097/MIB.0b013e3182802b6e. PMID: 23470502 Highlight from this Publication “FC determined by QPOCT was an accurate surrogate marker of “endoscopic remission”
Continue Reading

Other BÜHLMANN Fecal Calprotectin Assays Citations

Wright, E.K. et al., Cost-effectiveness of Crohn’s disease post-operative care, World J Gastroenterol. 2016 Apr 14;22(14):3860-8. doi: 10.3748/wjg.v22.i14.3860. Shentova, R. et al., 2016, Diagnostic Value of Fecal Calprotectin Point of Care Testing in the Pediatric Practice, Merit Res. J. Med. Med. Sci. Available online http://www.meritresearchjournals.org/mms/index.htm Gauss, A. et al., Quality of Life Is Related to

Continue Reading

Visit BUHLMANN Diagnostics Corp at AACC 2016

When: July 31 - August 4, 2016 Where: Philadelphia, PA Booth: #4202 Learn More: AACC 2016
Continue Reading

BÜHLMANN GanglioCombi™ MAG ELISA Utilized in Guillain-Barré Syndrome (GBS) and Zika Virus Study

The BÜHLMANN GanglioCombi™ MAG ELISA was recently utilized in a case-control study in French Polynesia focusing on individuals diagnosed with Guillain-Barré Syndrome (GBS). See publication below: Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study Learn More BÜHLMANN GanglioCombi® MAG ELISA is for Research Use Only. Not for use in diagnostic procedures in
Continue Reading

Connect with BUHLMANN Diagnostics Corp at MGCC 2016!

When: June 18 - 22, 2016 Where: Edmonton, AB Canada Booth: #307   More Information: Joint Conference of the Canadian College of Medical Geneticists and the Canadian Society of Clinical Chemists (MGCC 2016)
Continue Reading

Testing Potency and Efficacy of Inhibitors of P13K, SYK, BTK Activity

Inhibitors of PI3K, SYK and BTK pathways are a large focus for pharmaceutical companies with several small molecule inhibitors currently at different stages of development. Enzymatic assays measuring the direct activity of compounds are limited because they do not provide information about the entire pathway controlled by these kinases. If you are interested in learning
Continue Reading